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Summary
Osteochondromas occur as sporadic solitary lesions or
as multiple lesions, characterizing the hereditary multi-
ple exostoses syndrome (EXT). Approximately 15% of
all chondrosarcomas arise within the cartilaginous cap
of an osteochondroma. EXT is genetically heterogene-
ous, and two genes, EXT1 and EXT2, located on 8q24
and 11p11-p12, respectively, have been cloned. It is still
unclear whether osteochondroma is a developmental dis-
order or a true neoplasm. Furthermore, it is unclear
whether inactivation of both alleles of an EXT gene,
according to the tumor-suppressor model, is required for
osteochondroma development, or whether a single EXT
germline mutation acts in a dominant negative way. We
therefore studied loss of heterozygosity and DNA ploidy
in eight sporadic and six hereditary osteochondromas.
EXT1- and EXT2-mutation analysis was performed in
a total of 34 sporadic and hereditary osteochondromas
and secondary peripheral chondrosarcomas. We dem-
onstrated osteochondroma to be a true neoplasm, since
aneuploidy was found in 4 of 10 osteochondromas. Fur-
thermore, LOH was almost exclusively found at the
EXT1 locus in 5 of 14 osteochondromas. Four novel
constitutional cDNA alterations were detected in exon
1 of EXT1. Two patients with multiple osteochondro-
mas demonstrated a germline mutation combined with
loss of the remaining wild-type allele in three osteo-
chondromas, indicating that, in cartilaginous cells of the
growth plate, inactivation of both copies of the EXT1
gene is required for osteochondroma formation in he-
reditary cases. In contrast, no somatic EXT1 cDNA al-
terations were found in sporadic osteochondromas. No
mutations were found in the EXT2 gene.
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Introduction
Osteochondromas (or osteocartilaginous exostoses;
MIM 133700), defined as cartilage-capped bony pro-
tuberances developing from the juxta-epiphyseal regions
of the long bones, may occur as sporadic solitary lesions
or multiple lesions, characterizing the hereditary mul-
tiple exostoses syndrome (EXT). EXT is an autosomal
dominant skeletal disorder that, apart from the devel-
opment of multiple osteochondromas, is characterized
by deformities of the forearm and disproportionate short
stature. The histogenesis of osteochondroma is still a
matter of debate. Many consider it a perversion in the
direction of bone growth, resulting from aberrant epi-
physeal development, instead of a true neoplasm (Huvos
1991; Dorfman and Czerniak 1998). However, cyto-
genetic aberrations have been detected (Mertens et al.
1994; Bridge et al. 1998), suggesting a clonal neoplastic
growth.
The most serious complication of EXT is sarcomatous
degeneration, which is estimated to occur in !5% of
cases (Schmale et al. 1994; Wicklund et al. 1995). In
90% of cases, malignant transformation occurs within
the cartilaginous cap, leading to a secondary peripheral
chondrosarcoma (Willms et al. 1997). Approximately
15% of all chondrosarcomas are documented to arise
peripherally and secondary to an osteochondroma,
whereas 75% arise centrally in bone, usually without a
benign precursor (Mulder et al. 1993; Springfield et al.
1996).
EXT is genetically heterogeneous, and, at present, two
genes, EXT1 and EXT2, located on 8q24 and 11p11-
p12, respectively, have been cloned (Ahn et al. 1995;
Stickens et al. 1996; Wuyts et al. 1996). Furthermore,
linkage to chromosome 19p has been found, suggesting
the existence of an EXT3 gene (Le Merrer et al. 1994).
A tumor-suppressor function has been suggested (Hecht
et al. 1995; Raskind et al. 1995), on the basis of loss of
heterozygosity (LOH) in chondrosarcomas. Recently,
the EXT1 and EXT2 gene products were shown to be
glycosyltransferases required for the biosynthesis of he-
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paran sulfate (Lind et al. 1998; McCormick et al. 1998).
Furthermore, an EXT1 homologue in Drosophila (tout-
velu) was demonstrated to be required for diffusion of
the morphogen Hedgehog (Bellaiche et al. 1998).
Knudson (1971) postulated the two-hit model for tu-
mor-suppressor–gene inactivation. Both copies of the
gene must be inactivated to abolish the normal tumor-
suppressor activity. In hereditary cancer, the first hit usu-
ally consists of a germline mutation, which has been
extensively studied in EXT (Ahn et al. 1995; Stickens et
al. 1996; Hecht et al. 1997; Philippe et al. 1997; Wuyts
et al. 1998). The second hit is the inactivation of the
remaining wild-type copy, which occurs somatically, of-
ten either by deletion of part or all of the chromosomal
arm that harbors the gene or by mitotic recombination.
This results in LOH, detectable with polymorphic mark-
ers located in this chromosomal region. Analogously, in
sporadic tumors, LOH and mutational inactivation of
the retained allele are observed.
LOH at the EXT loci has been studied and detected
in chondrosarcomas only (Hecht et al. 1995; Raskind
et al. 1995). It is therefore still unclear whether the com-
plete inactivation of the EXT gene—and, thus, a second
somatic hit—is required for osteochondroma develop-
ment, or whetehr a single EXT germline mutation acts
in a dominant-negative way causing multiple benign os-
teochondromas. In the latter case, inactivation of the
remaining allele is a prerequisite for malignant trans-
formation. To address this, we performed a study of
LOH in eight sporadic and six hereditary osteochon-
dromas in combination with EXT1- and EXT2-muta-
tion analysis in a total of 34 sporadic and hereditary
osteochondromas and secondary chondrosarcomas.
Material and Methods
Material
Tumor tissues were retrieved from the files of the Lei-
den University Medical Center, a bone-tumor referral
center. Fresh-frozen cartilaginous tumor tissue was avail-
able for five cases of multiple osteochondromas of three
patients and for eight sporadic osteochondromas. Clin-
ical data regarding multiplicity of skeletal lesions and
family history were obtained by review of clinical charts.
If data were inconclusive, patients were asked to com-
plete a questionnaire, for which the response rate was
83%. An unequivocal family history was not always
available. The mean ages at operation were 20.5 years
(range 12.4–48.8 years) for sporadic cases (five males
and three females) and 24.8 years (range 20.7–27.0
years) for hereditary cases (three males). Of the three
patients with multiple osteochondromas, two had a neg-
ative family history. Blood of their relatives was not
available. Additionally, fresh-frozen tumor tissue of 23
chondrosarcomas secondary to osteochondroma was
used for mutation analysis. Both data from patients with
peripheral chondrosarcoma and LOH data have been
described previously by Bove´e et al. (in press). Of 20
patients, 6 demonstrated multiple osteochondromas, 3
of whom had an unequivocal positive family history for
EXT. For three other patients, multiplicity of osteo-
chondromas could not be determined.
DNA Isolation
DNA isolation of fresh-frozen tissue was performed
with proteinase-K digestion and phenol-chloroform ex-
traction, as described by Devilee et al. (1989), with some
modifications: before proteinase-K digestion, cartilagi-
nous tumor tissue was preincubated in a 3 M NaAc
buffer (pH 5.6), saturated with hyaluronidase, for 2 h
at 37C. Then, the pH was adjusted by addition of 18
vol 2 M NaOH. DNA from one osteochondroma of
patient 428 was derived from cultured cells. For four
osteochondromas, the tumor-cell fraction was purified
for LOH analysis by microdissection. Haematoxylin-
and eosin-stained cryostat sections were visually ex-
amined, and fields derived from the cartilaginous cap of
the osteochondroma were scraped from 20 adjacent,
stained, uncovered 10-mm cryostat sections, with use of
a scalpel or syringe. Sections were fixed in methanol 10
min before staining. DNA from this microdissected tis-
sue was isolated as described by Isola et al. (1994). DNA
from freshly collected blood samples obtained, with in-
formed consent, from the patients and 96 normal healthy
individuals was isolated with a salting-out procedure
(Miller and Polesky 1988).
EXT-Mutation Analysis
Mutation analysis was performed on tumor DNA
from 11 patients with osteochondromas (range
40%–90% for tumor percentages) and from 23 patients
with chondrosarcomas (range 50%–100%). Only one
osteochondroma from each patient with multiple osteo-
chondromas was included.
PCR
For exon 1 of the EXT1 gene, five overlapping frag-
ments were amplified, whereas the other exons were
covered with single PCR fragments as described by
Wells et al. (1997). Thermal cycling was performed in
a programmable heat block (Perkin-Elmer-Cetus) with
a “touchdown” PCR program of 47 cycles consisting
of 2 cycles with annealing at 65C, 2 cycles at 64C,
2 cycles at 63C, 2 cycles at 62C, 2 cycles at 61C, 2
cycles at 60C, 4 cycles at 59C, 6 cycles at 58C, and
25 cycles at 57C. Some modifications were made, as
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Table 1
Constitutional EXT1 cDNA Alterations Found in Four Patients
Parameter Patient 282 Patient 428 Patient 427 Patient 17
Diagnosis Chondrosarcoma Osteochondromas Osteochondromas Chondrosarcoma
Multiple osteochondromas? No Yes Yes Inconclusive
Family history Negative Positive Negative Inconclusive
cDNA change A117G G490C 702-717delCCCCTCTTTTCTAAG A947G
Protein change E39E D164H PLFSK235-239del N316S
Type of mutation Silent Missense In-frame deletion Missense
Method of confirmation Restriction BsiHKAI Hybridization 4% Agarose gel Hybridization
Frequency in normal individuals 0/92 0/89 0/96 0/92
LOH? Yes Yes Yesa No
a LOH detected in one of two osteochondromas.
follows: primers Apr111 and 211 were replaced by
primers CAGGCAGGACACATGCAG and CTGGA-
ATCCTCGTTTTCCAA, generating a product of 242
bp, with thermal cycling consisting of the touchdown
PCR program decreasing to 59C instead of 57C.
Primers Apr 109 and 209 were replaced by
GCTCCAGGTTCTACACCTCG and TACTGATG-
CTGGCTTTGGC, and 40 cycles with a constant an-
nealing temperature of 63C were applied, generating
a product of 249 bp. PCR was performed in a total
vol of 25 ml containing 15 pmol of each primer, 0.2
mM dNTP (Pharmacia), 50 mM KCl, 10 mM Tris (pH
8.3), 0.2 mg BSA/ml, 2 mM MgCl2, 1 U AmpliTaq or
AmpliTaq GOLD (Perkin-Elmer), and 1 mCi a[32P]-
dCTP (Amersham).
Amplification of the EXT2 exons was performed with
the primers and PCR conditions described elsewhere
(Wuyts et al. 1998). Both primers were 32P labeled with
T4 polynucleotide kinase (Pharmacia), and 32P-labeled
dCTP was incorporated during the amplification
process.
SSCP Analysis
SSCP analysis of the EXT1 gene was performed on a
gel with the GeneAmp Detection Gel kit (Perkin-Elmer),
according to the manufacturer’s recommendations, for
4 h at 12 W at room temperature. Additionally, samples
were mixed with an equal volume of formamide-loading
dye (90% formamide, 10 mM EDTA [pH 8.0], 0.3%
bromphenol blue, and 0.3% xylene-cyanol), denatured
for 5 min at 95C, and loaded onto a gel consisting of
10% glycerol, 6% polyacrylamide, and 1# Tris-borate
EDTA, for 6 h at 25 W at room temperature. Finally, a
6.5% polyacrylamide gel containing 7 M urea was run
under denaturing conditions, to study small insertions
or deletions. SSCP analysis of the EXT2 gene was per-
formed on an MDE polyacrylamide gel (FMC) with
10% glycerol for 16 h (500 V) at room temperature.
Gels were dried and exposed to x-ray films. PCR and
SSCP analysis were repeated on samples showing ab-
errant bands, and constitutional DNA from the same
patient was also analyzed.
Sequencing Analysis
PCR was repeated, without a[32P]-dCTP, on samples
showing aberrant bands on SSCP analysis, and PCR
products were purified with MicroSpin G-50 columns
(Pharmacia Biotech). Subsequent sequencing reactions
were performed, with the same primers and use of the
ABI Prism BigDye Terminator Cycle Sequencing Ready
Reaction Kit according to the manufacturer’s recom-
mendations (Perkin-Elmer Applied Biosystems). Both
strands were sequenced. Samples were run on the ABI
377 semiautomated sequencer (Perkin-Elmer). Se-
quences were analyzed with Factura 2.0.1 software (Per-
kin-Elmer) and were aligned with each other, and the
normal cDNA sequence (Ahn et al. 1995) electronically
by ClustalW multiple-sequence alignment (EMBL Out-
station European Bioinformatics Institute). Nucleotide
numbering was done on the basis of the sequence pro-
vided by Ahn et al. (1995), and mutation nomenclature
was according to the Nomenclature Working Group.
Testing for Sequence Variations
To confirm cDNA alterations and to exclude that these
alterations are polymorphisms occurring in the normal
population, PCR-fragment analysis was performed on
normal and tumor DNA of the patient and on periph-
eral-blood DNA from 89–96 normal healthy blood do-
nors, by use of either oligonucleotides designed to con-
tain the mismatch, restriction-enzyme analysis, or gel
electrophoresis (table 1). PCR products of EXT1 frag-
ments containing the mutated sequence (the third and
fifth fragment of exon 1) were blotted on nylon mem-
branes, as described by Devilee et al. (1991b). Oligon-
ucleotides TTTAGACAGACACCAGTTGT (G490C)
and GACAGAGACAGCACCGAGTA (A947G) were
hybridized on the blots at 50C and 60C, respectively.
Restriction-enzyme analysis was performed to study
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A117G by use of 2 ml PCR product (the first fragment
of exon 1) that was incubated with 2 U BsiHKAI (New
England BioLabs), and fragments were separated onto
1.5% agarose gels. The enzyme could only digest when
the cDNA alteration was present.
To study 702-717delCCCCTCTTTTCTAAG, PCR
products (the fourth fragment of exon 1) were electro-
phoresed on an agarose gel containing 3% NuSieve GTG
(FMC BioProducts) combined with 1% Seakem GTG
(FMC BioProducts).
LOH Study
Analysis of microsatellite markers was performed by
PCR on 100 ng DNA from each of 14 osteochondromas
from 11 patients, as described by Weber and May
(1989), with 1 mCi a[32P]-dCTP in a total vol of 12 ml.
Thermal cycling was performed in a programmable heat
block (MJ research) consisting of 27 cycles with an an-
nealing temperature of 55C. For PCR on microdissected
DNA, 33 cycles were applied. Apart from loci harboring
the EXT and EXT-like regions, primers were chosen in
regions described to be involved in chondrosarcoma, in-
cluding the p53 and Rb regions (Yamaguchi et al. 1996)
at 9p21 (Jagasia et al. 1996) and at chromosome 10
(Raskind et al. 1996) (table 2). Polymorphic markers are
described in the Genome Database. After electrophoresis
on a 6.5% polyacrylamide gel containing 7 M urea, gels
were dried and exposed to x-ray films. Signal intensities
were measured by Phosphor Imaging (Molecular Dy-
namics; see fig. 1). LOH was scored when the quotient
of the ratios of both alleles of normal and tumor samples
was 1.7 (Gruis et al. 1993). Ratios of 1.3–1.7 were
regarded as inconclusive and were excluded from the
analysis (Devilee et al. 1991a). LOH had to be repro-
ducible to be included.
Flow Cytometry
DNA-flow cytometry was performed on 12 osteo-
chondromas from 11 patients. Single-cell suspensions
from fresh-frozen tissue for single-parameter nuclear-
DNA flow cytometry (FCM) were prepared by use of
the method of Vindelov et al. (1983a). A minimum of
10,000 cells/sample was measured on an FACSCalibur
flow cytometer (Becton Dickinson). Trout red blood cells
served as an internal standard for determination of the
G0,1-cell DNA content (Vindelov et al. 1983b). Mod-
FitLT V2.0 software was used for data acquisition. DNA
histograms were evaluated according to accepted criteria
(Hiddemann et al. 1984).
Results
EXT Mutation Analysis
cDNA alterations were detected exclusively in exon 1
of the EXT1 gene in 4 (12%) of 34 samples (table 1
and fig. 1). Two (22%) of nine patients demonstrating
multiple osteochondromas showed a constitutional
EXT1 mutation. In addition, one patient with sporadic
chondrosarcoma and one patient with chondrosarcoma
for whom EXT status was unclear demonstrated con-
stitutional EXT1 cDNA alterations. No somatic alter-
ations were found.
The aberrant bands, displayed in figure 1, were de-
tected by both nondenaturing gel conditions. Denaturing
gel electrophoresis demonstrated an additional band in
patient 427 (fig. 1).
A DNA sequence variant (GAArGAG in codon 39)
that did not result in an amino acid change (GlurGlu)
was found in a sporadic peripheral chondrosarcoma-
tumor sample from patient 282 and was also hetero-
zygously present in DNA extracted from peripheral
blood from the same patient. This variant, which can
be detected by BsiHKAI digestion of the first fragment
of exon 1, proved to be rare, since it was not found in
the 33 other tumor samples or in 92 normal individuals.
However, the GAG codon is more frequent in human
than is the GAA codon (DNA Information and Stock
Center), thus excluding the possibility that this alteration
makes transcription of the DNA sequence more difficult
(Conrad et al. 1983). Combined with the lack of an EXT
phenotype, this finding implies that this silent alteration
is not disease causing.
A heterozygous constitutional missense mutation,
GACrCAC (AsprHis), was found in codon 164 of pa-
tient 428, demonstrating EXT with a positive family
history. A heterozygous constitutional 15-bp deletion of
codons 235–239, deleting Pro-Leu-Phe-Ser-Lys from the
protein, was detected in patient 427, demonstrating mul-
tiple osteochondromas with a negative family history.
Finally, in codon 316, a heterozygous missense altera-
tion, AACrAGC (AsnrSer), was found in constitutional
DNA from patient 17, with peripheral chondrosarcoma.
This patient did not demonstrate an obvious EXT phe-
notype and had a family history of “knee operations.”
None of these alterations was detected in DNA from
89–96 normal individuals.
LOH Analysis
LOH was detected by microsatellite analysis in six
osteochondromas, consisting of four sporadic and two
hereditary cases (table 2 and fig. 2). Five (36%) of 14
osteochondromas showed LOH restricted to chromo-
some 8q24, where the EXT1 gene is located. In two
sporadic cases LOH was found only for marker D8S522,
Bove´e et al.: Genetic Analysis of Osteochondromas 693
Table 2
Microsatellite Markers with Chromosomal Localization, and Percentage of
Heterozygosity
GENE AND MARKER
MARKER INFORMATION
FREQUENCY OF
OSTEOCHONDROMAS
WITH LOH a
Location
Heterozygosity
(%)
Sporadic
( )n = 8
Hereditary
( )n = 6
EXT1:
D8S85 8q23.3 .74 0/5 1/6
D8S547 8q24.11 .66 1/5 2/4
D8S522 8q24.12-13 .71 3/6 2/6
D8S198 8q24.13 .83 1/6 1/3
EXT2:
D11S905 11p13-p12 .74 0/7 0/1
D11S903 11p13-q13 .74 0/4 0/4
D11S554 11p11.2-12 .91 0/7 0/4
EXT3:
D19S216 19pter-qter .75 0/4 0/4
D19S413 19pter-qter .76 0/7 0/2
D19S221 19p13.2 .86 0/7 0/4
EXTL1:
D1S436 1p36 .75 0/6 0/4
D1S470 1p36 .76 0/7 0/5
EXTL2:
D1S206 1p11-12 .82 0/4 0/5
D1S248 1p11-12 .82 1/7 0/3
EXTL3:
D8S1130 8p12-p22 .93 0/7 0/3
GATA119C06 8p12-p21 0/5 0/4
D8S283 8p12-p21 .78 0/6 0/4
D8S1820 8p .73 0/6 0/6
p16/p15:
D9S43 9p21 .83 0/4 0/2
D9S171 9p21 .80 0/5 0/2
10:
D10S89 10pter-p11.2 .80 0/7 0/6
D10S604 10pter-qter .66 0/6 0/4
D10S538 10pter-qter .73 0/4 0/3
D10S109 10q11.2-qter .71 0/8 0/6
D10S110 10q11.2-qter .58 0/4 0/0
Rb:
D13S153 13q14.1-14.3 .82 0/7 0/4
D13S155 13q14.3-q21.2 .83 0/7 0/6
p53:
TP53 17p13.1 .69 0/7 0/6
D17S513 17p13.3 .89 0/4 0/3
a Frequencies of LOH for osteochondromas are given as the no. of tumors showing
LOH/the no. of informative cases.
with retention of adjacent markers, whereas in one he-
reditary and one sporadic case the whole chromosome
arm was involved (table 3). One additional osteochon-
droma demonstrated LOH at D1S248, a marker flank-
ing the EXTL2 gene. Four sporadic and four hereditary
osteochondromas showed retention of heterozygosity at
all loci tested. Apart from the loci at 8q and 1p, none
of the other loci demonstrated LOH in osteochondroma.
In total, three (38%) of eight sporadic and two (33%)
of six hereditary osteochondromas demonstrated LOH
at 8q24.
In the two EXT patients demonstrating germline
cDNA alterations, loss of the wild-type allele was dem-
onstrated in three of four osteochondromas. In patient
428, sequence analysis demonstrated the predominance
of the mutated allele—and, thus, loss of the wild-type
allele—in both osteochondroma samples, compared
with normal DNA (fig. 1). LOH at D8S547 and D8S522
was found in one of them (fig. 2). In patient 427, one
of two osteochondromas demonstrated loss of the wild-
type allele (fig. 1), on the denaturing gel, and LOH, on
microsatellite analysis. The chondrosarcoma of patient
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Figure 1 Upper panel, aberrant bands (indicated by arrows) detected by SSCP analysis in both normal (only shown for patient 427) and
tumor DNA of four patients. Middle panel, corresponding sequence data. In patient 428, both normal and tumor DNA are shown, which
illustrates the predominance of the mutated allele and thus loss of the wild-type allele in both osteochondromas. Lower panel, confirmation of
cDNA alterations and screening of normal individuals. The A117G variant of patient 282 generated a BsiHKAI restriction site. Normal DNA
of this patient could also be digested (not shown). The mutations G490C (patient 428) and A947G (patient 17) were confirmed by oligo
hybridization. For patient 427, the PCR fragment containing the mutation was run on a denaturing gel, illustrating loss of the wild-type allele
(arrow) in one of two osteochondromas. Abbreviations: N = normal, T = tumor DNA, and C = control DNA from normal individual.
282 demonstrated LOH on microsatellite analysis,
whereas the chondrosarcoma of patient 17 did not show
LOH on either microsatellite analysis or sequence
analysis.
DNA Flow Cytometry
Four of 10 osteochondromas showed DNA aneuplo-
idy. DNA indices are listed in table 3. For two osteo-
chondromas, adequate DNA histograms could not be
obtained because of low cellularity. Six osteochondro-
mas showed a diploid DNA content. Three osteochon-
dromas showed an aneuploid DNA content, with DNA
indices of 1.14, 1.17, and 1.2. One osteochondroma
demonstrated a hypodiploid (DNA index 0.88) as well
as a hyperdiploid (DNA index 1.13) clone.
Discussion
Until now, it has been unclear whether an osteochon-
droma is a developmental disorder or a true neoplasm.
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Figure 2 Examples of autoradiograms on LOH analysis. Mi-
crosatellite markers are indicated above each panel. Allelic-imbalance
ratios, as measured by phosphor imaging, are indicated below each
panel. For patient 260, tumor DNA was microdissected, and for pa-
tient 428, T2 tumor DNA was isolated from cultured cartilaginous
tumor cells. In both hereditary cases LOH was found in one of two
osteochondromas, by microsatellite analysis. Abbreviations: N = nor-
mal DNA, T = tumor DNA, and CL = complete loss.
Furthermore, it is unknown whether the complete in-
activation of an EXT gene, according to the tumor-sup-
pressor model, is required for osteochondroma devel-
opment, or whether a single EXT germline mutation acts
in a dominant-negative way causing multiple benign os-
teochondromas. In the latter case, inactivation of the
remaining allele would be a prerequisite for malignant
transformation. The current study provides substantial
proof that osteochondroma is a true neoplasm and that
EXT1 is compatible with the tumor-suppressor–gene
model in osteochondroma. We studied LOH and DNA
ploidy in eight cases of sporadic and in six cases of
multiple osteochondromas. Furthermore, the EXT1 and
EXT2 genes, which were reported to show linkage in
∼70% of the EXT families (Legeai-Mallet et al. 1997a;
Raskind et al. 1998), were screened for mutations in a
total of 34 sporadic and hereditary osteochondromas
and secondary peripheral chondrosarcomas.
Osteochondroma is generally considered a perversion
in the direction of bone growth, resulting from aberrant
epiphyseal development with displacement of physeal
cartilage subsequently growing at right angles to the
bone, instead of as a true neoplasm. This is because the
lesion is formed by enchondral ossification and because
the bone substance produced is in every way normal
(Huvos 1991; Dorfman and Czerniak 1998). In the pre-
sent study, however, we show osteochondroma to be a
true neoplasia, since the presence of LOH in 6 of 14 and
of aneuploidy in 4 of 10 osteochondromas indicates a
clonal origin for the cartilaginous tissue of osteochon-
droma. Also, in the literature, clonal karyotypic abnor-
malities have been described (Mertens et al. 1994; Bridge
et al. 1998). It remains unclear, however, whether cells
forming the stalk of osteochondroma are also neoplastic
or are reactive.
EXT1-mutation analysis was performed by running
PCR fragments, of size 203–271 bp, on two nondena-
turing gels with different SSCP conditions, to improve
the detection rate (Sheffield et al. 1993). However, all
band shifts were detected under both conditions. There-
fore, the EXT2 fragments were analyzed under only one
condition. Four constitutional cDNA alterations of the
EXT1 gene were found. Of nine patients demonstrating
multiple osteochondromas, only two (22%) demon-
strated a constitutional EXT1 mutation, whereas no
EXT2 mutations were found. This is lower than what
would be expected on the basis of linkage (Legeai-Mallet
et al. 1997a). However, an adequate family history was
not always available, and in only five of nine cases with
multiple osteochondromas was an unequivocal positive
family history reported, although EXT is considered to
have a high, although incomplete, penetrance (Wicklund
et al. 1995; Legeai-Mallet et al. 1997b). Therefore, the
remaining four patients may also have multiple osteo-
chondromas in a setting other than familial EXT, such
as Langer Gideon syndrome. In addition, the low mu-
tation incidence may be explained in part by the
70%–90% sensitivity of SSCP mutation analysis. It has
also been reported that analysis of the open reading
frame of EXT1 does not always result in the identifi-
cation of a mutation in families demonstrating linkage
to 8q24 (Hecht et al. 1997; Wells et al. 1997).
The cDNA alterations found in the present study have
not been described previously (Wuyts et al. 1998 review
all mutations). Remarkably, all alterations were located
in exon 1, whereas only 40% of described mutations
occur in exon 1 (Wuyts et al. 1998). Furthermore, in
contrast to most EXT1 alterations described—80% of
which result in a truncated protein and 20% of which
are missense—no frameshifts leading to truncation were
found in the present study. This may be due to the pop-
ulation of both sporadic and hereditary osteochondro-
mas and chondrosarcomas, which is different from the
populations comprising exclusively patients with EXT
that have been analyzed so far.
Evidence that both copies of the EXT1 gene need to
be inactivated to allow the development of an osteo-
chondroma is provided by the two patients with EXT
in the present study, demonstrating, in three of four os-
teochondromas, EXT1 germline mutations combined
with loss of the wild-type allele. One osteochondroma
failed to show LOH, indicating that a small somatic
mutation could have inactivated the wild-type allele. The
amount of DNA from fresh-frozen tumor tissue avail-
able from this osteochondroma was not enough to allow
us to detect this possible mutation.
LOH found exclusively at 8q24 in 5 of 14 osteo-
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Table 3
Results of EXT1-Mutation Analysis, LOH Analysis, and DNA-Flow Cytometry for 11 Patients with Osteochondroma
PATIENT
MULTIPLE
OSTEOCHONDROMAS
LOH AT MARKERa
LOHb
(%)
DNA
INDEX
EXT1
MUTATION D8S85 D8S547 D8S522 D8S198
272 No No R R L R 8 )
260 No No NI L L L 8 1.0
165 No No R R NI R 0 1.20
425 No No R NI NI R 0 1.14
13 No No NI NI R NI 8 1.0
396 No No R R R R 0 1.0
481 No No R R L R 8 1.0
484 No No NI ) R NI 0 .881.13
277 ( )n = 2 Yes No R NI R NI 0 1.0
428 ( )cn = 2 Yes Yes R L L ) 8 )
427 ( )cn = 2 Yes Yes L L L L 8 1.17
NOTE.—LOH and ploidy data for peripheral chondrosarcomas were described previously by Bove´e et al. (in press).
Abbreviations: L = LOH, R = retention of heterozygosity, and NI = homozygous for the marker investigated.
a For loci 8q24.
b For all loci. Percentage of LOH was calculated, per tumor, as the percentage of loci showing LOH.
c Only the osteochondroma showing LOH on microsatellite analysis is given.
chondromas points to an important role for the EXT1
gene in the development of osteochondromas. Cytoge-
netic abnormalities involved 8q22-24.1 in 10 of 30 spo-
radic and in 1 of 13 hereditary osteochondromas (Mer-
tens et al. 1994; Bridge et al. 1998). In contrast, the
EXTL2 locus was the only other locus demonstrating
LOH in one sporadic osteochondroma, whereas in the
literature a deletion of 11p11-13 was observed in one
sporadic osteochondroma (Bridge et al. 1998). This sug-
gests that, in contrast to hereditary cases—in which all
three EXT loci may be involved with a slight predom-
inance of EXT1 over EXT2 and EXT3 (Legeai-Mallet
et al. 1997a; Raskind et al. 1998)—in sporadic cases
almost exclusively EXT1 is involved.
If the tumor-suppressor function of the EXT1 gene is
eliminated in an epiphyseal cartilage cell, then probably
normal regulation of chondrocyte proliferation is dis-
turbed, giving rise to a clonal proliferation with normal
differentiation. Both the role of the resulting altered he-
paran-sulfate expression on the cell surface (Lind et al.
1998; McCormick et al. 1998) and the abnormal dif-
fusion of the Hedgehog proteins (Bellaiche et al. 1998)
still need to be investigated. Indian Hedgehog is nor-
mally expressed in the growth zone and prehypertrophic
chondrocytes of cartilage (Hammerschmidt et al. 1997).
However, in sporadic osteochondromas no mutations
were detected. So far, only one somatic mutation in the
EXT1 gene has been described in a sporadic chondro-
sarcoma (Hecht et al. 1997). Future studies on a larger
panel of tumors should reveal whether the situation is
similar to the BRCA1 gene, for which only germline
mutations in hereditary breast cancer have been de-
scribed. In sporadic breast cancer, no somatic mutations
in BRCA1 are found, whereas LOH at 17q is a frequent
phenomenon (Futreal et al. 1994). It is also possible that
either mutations in regulatory sequences or large dele-
tions of EXT1 may occur or that alternative mechanisms
of inactivation may act, for instance, as transcriptional
down-regulation. Investigation of transcriptional inac-
tivation will entail northern analysis or immuno-
histochemistry. However, so far, EXT1 antibodies are
not available. Alternatively, mutations in EXT1 may not
be critical to the development of sporadic osteochon-
droma, and, instead, another locus at 8q may be
involved.
In a previous study, we investigated LOH and DNA
ploidy in 20 peripheral chondrosarcomas. In contrast to
chondrosarcomas not secondary to osteochondroma, a
high percentage of LOH was found at all loci studied
in peripheral chondrosarcoma, and DNA indices had a
range of 0.56–2.01 (Bovee et al., in press). Combining
those results and data from the present study, we want
to propose a genetic-progression model for peripheral
cartilaginous tumorigenesis. First, inactivation of both
copies of the EXT1 gene in cartilaginous cells of the
growth plate is required for osteochondroma formation,
as was shown by loss of the remaining wild-type allele
in hereditary osteochondromas in the present study.
Whether complete inactivation occurs in sporadic cases
remains to be investigated. One or more additional ge-
netic alterations are then required for peripheral chon-
drosarcomas to arise within the benign precursor. The
process of malignant transformation is genetically rep-
resented by chromosomal instability and may be caused
by defective cell-cycle checkpoints. We showed mild
aneuploidy to be present in the benign precursor, with
DNA indices showing a range of 0.88–1.2, whereas in
the peripheral chondrosarcomas more-severe aneuploidy
Bove´e et al.: Genetic Analysis of Osteochondromas 697
is seen, with DNA indices of 0.56–2.01. Additionally,
in osteochondromas LOH is restricted to 8q24, whereas
in its malignant counterparts a high percentage of LOH
is found at all loci tested.
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